Pfenex (PFNX) Stock Price, News & Analysis

Company Overview

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $12.75 to $12.75
• 50-Day Range: N/A
• 52-Week Range: $5.26 to $14.00
• Volume: N/A
• Average Volume: 503,865 shs
• Market Capitalization: $437.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PFNX Stock Analysis - Frequently Asked Questions

How were Pfenex's earnings last quarter?

Pfenex Inc. (NYSEAMERICAN:PFNX) released its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.07. The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $3.75 million.
Read the conference call transcript.

How do I buy shares of Pfenex?

Shares of PFNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pfenex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfenex investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD) and Ocular Therapeutix (OCUL).

Company Calendar

• Last Earnings: 5/07/2020
• Today: 12/23/2024

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:PFNX
• Previous Symbol: NYSEMKT:PFNX
• CUSIP: N/A
• CIK: N/A
• Web: www.pfenex.com
• Phone: +1-858-3524400
• Fax: N/A
• Employees: 71
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,297,000
• Free Float: N/A
• Market Cap: $437.29 million
• Optionable: Not Optionable
• Beta: N/A